Qiagen (NYSE: QGEN) posted an update on its Q3 earnings guidance this Tuesday. The EPS guidance stands at $0.58 for this quarter beating the Thomas Reuters estimate of $0.56. Revenue stands at $481.3 million as opposed to the consensus estimate of $462.67million.

NYSE: QGEN Quarterly Earnings Report Estimates

NYSE: QGEN posted its last quarterly earnings report on August 4. It reported a $0.55 EPS for that quarter which was at par with the consensus estimate. The company had 0.86% as net margin and 15.85% as return on equity. Revenue stood at $443.30 million for that quarter which was marginally up from the consensus estimate of $441.80.

According to several analysts’ reports, NYSE: QGEN’s increased by 16.2% as compared to this quarter last year.

On Tuesday, the NYSE: QGEN shares opened at $54.46. The 50-day moving average stands at 451.02 and the 200-day moving average of the company is $45.78.

Many brokerages have commented on NYSE: QGEN recently. Deutsche Bank upgraded Qiagen’s rating from “hold” to “buy” on August 14. The target price was increased from $32.00 to $60.00. Among others, Exane BNP Paribas increased NYSE: QGEN’s rating to “outperform”. The Bank of America set a target price of $59.00 on Qiagen stocks and upgraded its rating to “buy” from “sell”.

The consensus on the company’s rating now stands at “Buy”. According to analysts’ reports, the average target price for NYSE: QGEN is set at $50.72.

About Qiagen (NYSE: QGEN)

This company is a provider of sample and assay technologies for molecular diagnostics, academic and pharmaceutical research, applied testing, and so on.